Plain English Summary
Background and study aims
Multiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers. The therapy varies from chemotherapy, autologous bone marrow transplant, to novel agents . Chemotherapy for myeloma with Melphalan and prednisone produces an objective response in 50–60% of patients.
Curcumin is a natural polyphenol compound derived from turmeric (Curcuma longa). A number of preclinical studies have demonstrated that curcumin has anticancer effects against a variety of tumors, myeloma, both in vitro and in vivo. The safety of curcumin has been approved by the Food and Drug Administration and World Health Organization; In addition, its safety is strongly supported by the fact that this agent has been used in traditional Indonesia, India and Chinese medicine
The primary outcome of this study was to prove the efficacy of curcumin in the improvement of the remission status in myeloma patient. The secondary outcome was to evaluate the effect of curcumin to various disease activity, including NF-κB, IL-6, VEGF, TNF-α, CRP, and LDH.
Who can participate?
Multiple myeloma patients aged over 18 years who are ineligible for transplant
What does the study involve?
Patients will be randomly allocated to receive chemotherapy alone or chemotherapy plus curcumin for four 28 day cycles.
What are the possible benefits and risks of participating?
If the administration of curcumin can improve remission in the sample population, it certainly can be proposed as a useful complementary therapy
Where is the study run from?
Dr Kariadi General Hospital, Indonesia
When is the study starting and how long is it expected to run for?
February 2016 to February 2017
Who is funding the study?
LPDP (Lembaga Pengelola Dana Pendidikan), Indonesia
Who is the main contact?
Dr Damai Santosa
The effect of curcumin on remission status and survival on myeloma patients treated with melphalan prednisone: a pilot randomized clinical trial
1. The addition of curcumin to treatment will increase overall remission in myeloma patients treated with melphalan prednisone
2. The addition of curcumin to treatment will decrease measures of NF-κB, IL-6, VEGF, TNF-α, CRP, and LDH in myeloma patients treated with melphalan prednisone
Approved 17/02/2016, Komisi Etik Penelitian Kesehatan (Jl. Dr. Soetomo No18, Semarang City, Central Java Province, Indonesia, 50244; +62243818550), ref: 16/EC/FK-RSDK/I/2016
Interventional randomized controlled trial
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
See additional files (in Indonesian)
Patients were allocated randomly in two parallel study groups using a sealed envelope method. The treatment group (17 patients) was treated with MP regimen (melphalan 4mg/m², prednisone 40mg/m², for 7 days) and curcumin 8 grams/daily for 28 days. The control group (16 patients) was treated with MP regimen and placebo. All of the patients were evaluated every 28 days for a total of 4 cycles treatment.
Each patient was followed up every 28 days, for 4 cycles. A checklist was used for data collection and filled in each visit separately. The contents of checklist were the patients' profiles (age, sex, education level), and laboratory data, including full blood count (FBC), urea, creatinine, NF-kB, IL-6, CRP, LDH, VEGF, and patient group (treatment or control). The physical exam of the patients was performed by a physician every visit (single blindness). Remission and TNF-a was evaluated after the end of study
Primary outcome measure
Overall remission at the end of the study period
Secondary outcome measures
Levels of NF-kB, TNF-a, VEGF, IL-6, CRP, LDH measured using blood test every 28 days throughout the study period
Overall trial start date
Overall trial end date
Reason abandoned (if study stopped)
Participant inclusion criteria
1. New multiple myeloma patients
2. Aged over 18 years old
3. Ineligible for transplant
Target number of participants
20 participants, 10 in each group
Participant exclusion criteria
2. Severe infection
4. Patients with severe disease (such as acute hepatitis, chronic hepatitis, cirrhosis)
5. Elevation of aspartate aminotransferase (AST) >3 times upper limit normal (ULN)
6. Participated in another study
7. Poor performance status
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
dr. Kariadi General Hospital
Jl. Dr. Sutomo no 16
LPDP (Lembaga Pengelola Dana Pendidikan)
Ministry of Finance of Republic of Indonesia
dr. Wahidin Raya Street No1
Lembaga Pengelola Dana Pendidikan (LPDP)
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Thesis defence in Faculty of Medicine, Diponegoro University, March 2018
IPD sharing statement:
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. please contact Ms Haidi/Kiki, email address; firstname.lastname@example.org, type of data=excel, the data will become available for 10 years, the access criteria data will be shared including with hematologist that interesting in myeloma research, the types of analyses dependent on their study purpose, and the mechanism; please send email to us with the study protocol and we will discuss to our ethical committee
Intention to publish date
Participant level data
Available on request
Basic results (scientific)